VivoSim Labs, INC.
VIVS- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001497253
In the last 90 days, VivoSim Labs, INC. insiders filed 1 open-market purchase and 0 sales; 25 institutions reported holding it in 13F filings for Q3 2026, worth $109.7K in total; no superinvestor holds it.
- Currency
- USD
- Source
- SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
- Updated
- Nov 13, 2026, 1:19 AM ET
Revenue flow, FY2026
Where the revenue went in FY2026, from the income statement below. Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue; hover over a band or a bar for the exact amount.
Net loss for FY2026: $13.8M (10567.2% of revenue).
Income statement
Each column is one fiscal year, newest first.
| Line item | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|---|
| Period end | Mar 31, 2026 | Mar 31, 2025 | Mar 31, 2024 | Mar 31, 2023 | Mar 31, 2022 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | – | Apr 2, 2025 | – | – | – |
| Revenue | $131.0K | $144.0K | $109.0K | $370.0K | $1.50M |
| Cost of revenue | $0 | $5.00K | – | – | – |
| Research and development | $4.19M | $5.03M | $5.50M | $8.88M | $3.32M |
| Selling, general and administrative | $7.43M | $7.73M | $9.70M | $9.22M | $9.66M |
| Operating income | -$11.5M | -$12.6M | -$15.1M | -$17.7M | -$11.5M |
| Income tax | $2.00K | $2.00K | $2.00K | $2.00K | $2.00K |
| Net income | -$13.8M | -$2.49M | -$14.7M | -$17.3M | -$11.4M |
| EPS, basic | $-5.35 | $-1.70 | $-1.60 | $-1.98 | – |
| EPS, diluted | $-5.35 | $-1.70 | $-1.60 | $-1.98 | – |
| Weighted shares, basic | 2.59M | 1.46M | 9.14M | 8.71M | – |
| Weighted shares, diluted | 2.59M | 1.46M | 9.14M | 8.71M | – |
| Margins and growth | |||||
| Operating margin | -8768.7% | -8761.1% | -13840.4% | -4792.2% | -765.3% |
| Net margin | -10567.2% | -1727.8% | -13459.6% | -4664.6% | -763.2% |
| Revenue growth, year over year | −9.0% | +32.1% | −70.5% | −75.3% | – |
Balance sheet
Each column is one fiscal year, newest first.
| Line item | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|---|
| Period end | Mar 31, 2026 | Mar 31, 2025 | Mar 31, 2024 | Mar 31, 2023 | Mar 31, 2022 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | – | Apr 2, 2025 | – | – | – |
| Cash and equivalents | $5.02M | $11.3M | $2.90M | $15.3M | $28.7M |
| Accounts receivable | $32.0K | $30.0K | $33.0K | $152.0K | – |
| Inventory | – | $0 | $297.0K | – | – |
| Total current assets | $6.63M | $12.1M | $3.94M | $17.0M | $29.5M |
| Property, plant and equipment | $206.0K | $419.0K | $669.0K | $902.0K | $662.0K |
| Total assets | $7.39M | $14.7M | $6.35M | $20.3M | $33.3M |
| Accounts payable | $1.02M | $1.64M | $627.0K | $331.0K | $415.0K |
| Total current liabilities | $2.79M | $3.74M | $1.86M | $3.67M | $1.38M |
| Total liabilities | $8.48M | $4.16M | $2.75M | $4.98M | $3.09M |
| Shareholders' equity | -$1.10M | $10.5M | $3.60M | $15.3M | $30.2M |
Cash flow statement
Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.
| Line item | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|---|
| Period end | Mar 31, 2026 | Mar 31, 2025 | Mar 31, 2024 | Mar 31, 2023 | Mar 31, 2022 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | – | Apr 2, 2025 | – | – | – |
| Operating cash flow | -$10.8M | -$9.46M | -$14.7M | -$12.4M | -$8.45M |
| Capital expenditures | $0 | $13.0K | $42.0K | $396.0K | $409.0K |
| Free cash flow | -$10.8M | -$9.47M | -$14.7M | -$12.8M | -$8.86M |
| Depreciation and amortization | $215.0K | $266.0K | $280.0K | $293.0K | $142.0K |
| Stock-based compensation | $303.0K | $532.0K | $1.51M | $2.38M | $2.26M |
| Share buybacks | – | – | – | – | $0 |
| Investing cash flow | $94.0K | $9.03M | $816.0K | -$966.0K | -$409.0K |
| Financing cash flow | $4.45M | $8.85M | $1.44M | $0 | $205.0K |
| Net change in cash | -$6.29M | $8.41M | -$12.4M | -$13.4M | -$8.66M |
| Ratio | |||||
| Stock-based compensation, % of revenue | 231.3% | 369.4% | 1383.5% | 642.4% | 150.4% |
Shares outstanding
Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.
| Cover date | Shares outstanding | Change in a year | Filing |
|---|---|---|---|
| Nov 1, 2026 | 20.3M | +677.7% | SEC |
| Aug 10, 2026 | 14.9M | +471.2% | SEC |
| Jul 10, 2026 | 3.49M | +34.4% | SEC |
| Feb 1, 2026 | 2.61M | −85.1% | SEC |
| Nov 1, 2025 | 2.61M | −83.0% | SEC |
| Aug 1, 2025 | 2.60M | −83.1% | SEC |
| Jun 1, 2025 | 2.60M | −81.9% | SEC |
| Feb 1, 2025 | 17.5M | +73.8% | SEC |
Notes and known gaps
How these numbers are put together, and what they can't tell you.
- Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
- Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.
Known gaps
- Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
- EPS and share counts are as reported at the time, not adjusted for later stock splits. Stock splits since Mar 31, 2021, from 13F share counts: 1-for-12 in Q1 2025.
- For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
- For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
- Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
- Depreciation and amortization is missing for some companies that report it under their own XBRL tags.